BR112016016674A2 - Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla - Google Patents

Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla

Info

Publication number
BR112016016674A2
BR112016016674A2 BR112016016674A BR112016016674A BR112016016674A2 BR 112016016674 A2 BR112016016674 A2 BR 112016016674A2 BR 112016016674 A BR112016016674 A BR 112016016674A BR 112016016674 A BR112016016674 A BR 112016016674A BR 112016016674 A2 BR112016016674 A2 BR 112016016674A2
Authority
BR
Brazil
Prior art keywords
therapeutic
multiple sclerosis
prophylactic agent
treatment
active ingredient
Prior art date
Application number
BR112016016674A
Other languages
English (en)
Inventor
TAKAGAKI Kozue
Kaino Mie
Hirokawa Hiroe
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BR112016016674A2 publication Critical patent/BR112016016674A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

AGENTE TERAPÊUTICO OU PROFILÁTICO PARA ESCLEROSE MÚLTIPLA. O propósito da presente invenção é prover um agente terapêutico ou profilático para esclerose múltipla, que contém um composto não esteroidal de peso molecular baixo como um ingrediente ativo. A presente invenção provê um agente terapêutico ou profilático para esclerose múltipla, que contém um derivado de ciclo-hexano tipificado por um composto mostrado abaixo ou um sal farmaceuticamente aceitável do mesmo como um ingrediente ativo.
BR112016016674A 2014-01-29 2015-01-29 Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla BR112016016674A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014014063 2014-01-29
JP2014154893 2014-07-30
PCT/JP2015/052420 WO2015115509A1 (ja) 2014-01-29 2015-01-29 多発性硬化症の治療剤又は予防剤

Publications (1)

Publication Number Publication Date
BR112016016674A2 true BR112016016674A2 (pt) 2017-08-08

Family

ID=53757081

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016016674A BR112016016674A2 (pt) 2014-01-29 2015-01-29 Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla

Country Status (8)

Country Link
US (2) US20170000767A1 (pt)
EP (1) EP3100726A4 (pt)
JP (1) JP6447496B2 (pt)
CN (1) CN105934245B (pt)
BR (1) BR112016016674A2 (pt)
CA (1) CA2933018C (pt)
MX (1) MX367576B (pt)
WO (1) WO2015115509A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181859A1 (ja) * 2017-03-31 2018-10-04 東レ株式会社 抗がん剤誘発末梢神経障害の治療剤又は予防剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101065A (ja) * 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
CA2381215A1 (en) * 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
JP2001114690A (ja) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd ｐ３８ＭＡＰキナーゼ阻害剤
WO2008105383A1 (ja) 2007-02-26 2008-09-04 Toray Industries, Inc. ピラゾール誘導体およびその医薬用途
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
WO2011126903A2 (en) 2010-03-30 2011-10-13 Verseon, Inc. Multisubstituted aromatic compounds as inhibitors of thrombin
CN102822148B (zh) 2010-03-31 2015-03-11 东丽株式会社 纤维肌痛综合征的治疗剂或预防剂
MX2012010766A (es) * 2010-03-31 2012-10-15 Toray Industries Agente terapeutico o agente preventivo para el trastorno de recoleccion de orina.
PL2565184T3 (pl) * 2010-04-28 2016-06-30 Toray Industries Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera
WO2012015027A1 (ja) 2010-07-30 2012-02-02 東レ株式会社 神経障害性疼痛の治療剤又は予防剤

Also Published As

Publication number Publication date
CN105934245B (zh) 2019-04-09
MX2016009932A (es) 2017-01-11
EP3100726A4 (en) 2017-06-14
US20170231960A1 (en) 2017-08-17
JPWO2015115509A1 (ja) 2017-03-23
MX367576B (es) 2019-08-27
CA2933018A1 (en) 2015-08-06
CN105934245A (zh) 2016-09-07
JP6447496B2 (ja) 2019-01-09
US20170000767A1 (en) 2017-01-05
EP3100726A1 (en) 2016-12-07
US10130608B2 (en) 2018-11-20
CA2933018C (en) 2021-10-26
WO2015115509A1 (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CR20150481A (es) Composición farmacéutica de clorhidrato de s-ketamina
DOP2016000253A (es) Nuevos compuestos
BR112014025711A8 (pt) composto, medicamento, e, uso de um composto
AR103680A1 (es) Inhibidores selectivos de bace1
BR112016017317A2 (pt) composto, antagonista de trpa1, medicamento, e, uso de um composto
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
UY36123A (es) Derivados de carboxamida
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time